Results 51 to 60 of about 297,165 (214)
Background Chimeric antigen receptor (CAR) T-cell therapy is effective in treating B-cell malignancies, however relapse due to lack of CAR persistence and antigen-modulated escape remains common. Multiple strategies to simultaneously target CD19 and CD22
Terry J Fry +5 more
doaj +1 more source
Introduction: Cellular immunotherapy has greatly improved cancer treatment in recent years. For instance, chimeric antigen receptor (CAR) T cell therapy has been proven highly effective in treating hematological malignancies, and many CAR cell designs ...
YangHao Fu +3 more
doaj +1 more source
Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells [PDF]
Abstract T cells gene-modified to express chimeric Ag receptors (CARs) have shown potent antitumor activity in vivo and are in clinical trials at locations worldwide. However, CAR activity has been investigated in mouse models in which Ag expression is restricted to the tumor.
Cheadle, Eleanor J. +5 more
openaire +2 more sources
BCG vaccination potentiates oxidative phosphorylation in neonatal myeloid‐derived suppressor cells
BCG vaccination enhances oxidative phosphorylation in neonatal MDSCs, impairing their immunosuppressive function. It upregulates electron transport chain genes and mitochondrial activity, increasing ATP and oxygen consumption. Pharmacological OXPHOS inhibition partially restores suppressive capacity, confirming causality.
Yingying Chen, Hui Li
wiley +1 more source
Background Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy.
Na Yang +11 more
doaj +1 more source
Association Between Serum Ferritin and CD19/CD34 Expression in Pediatric Acute Lymphoblastic Leukemia [PDF]
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, characterized by malignant proliferation and accumulation of lymphoblasts in the bone marrow.
Karrar Tikki, Haider Jaffat
doaj +1 more source
Abstract 3768: CAR T cells specific for CD19 can be redirected to kill CD19 negative tumors
Introduction. Remarkable progress has been made in the treatment of relapsed/refractory Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma with CAR-CD19 T cells. In contrast, progress against CD19-negative hematological cancers and solid tumors has been
Paul D. Rennert +4 more
core +1 more source
Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui +10 more
wiley +1 more source
CD9+ B Cells Induce T Follicular Helper Cell Apoptosis to Regulate Germinal Center Regression
A unique subset of CD9+ B cells regulates germinal center B (GC‐B) cell regression by inducing T follicular helper (Tfh) cell apoptosis through multiple signaling pathways, such as ALCAM‐CD6. FOXP1 plays a key role in GC‐B cell differentiation. These findings clarify mechanisms of GC degeneration and termination and offer potential targets for adenoid ...
Wenjing Liao +27 more
wiley +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Development of chimeric antigen receptor T‐cell therapy has revolutionized the treatment of B‐cell malignancies, although challenges such as antigen escape and tumor heterogeneity often decrease treatment success. Modular CARs targeting multiple antigens
Pablo Gonzalez‐Garcia +9 more
doaj +1 more source

